Fitusiran antithrombin-based dose regimen targeting 15%-35% of antithrombin activity demonstrated favorable safety profile in male participants aged ≥ 12 years with severe hemophilia A or B ...

A group of leading American scientists has issued a chilling warning to the public after confirming that Covid mRNA “vaccines” trigger Acquired Hemophilia A (AHA) – a deadly autoimmune bleeding ...

Hemophilia is a serious condition that can limit the ability to avoid episodes of bleeding. Treatment includes regular infusions of proteins to replace what the body doesn’t produce naturally ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off ...

Hemophilia is a rare bleeding disorder characterized by low levels of proteins called “clotting factors.” Hemophilia is an inherited blood disorder in which your blood does not clot properly ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved fitusiran (Qfitlia, Sanofi) for routine prophylaxis for prevention or reduction in bleeding ...

"Hemophilia is pretty rare ... "You've got parents around the country who are having to give their kids shots every other week, every month and it hurts. And it's hard to do something to your ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without inhibitors. Fitusiran is a first-in-class small interfering RNA ...

BioMarin’s BMRN Roctavian, an adeno-associated virus-based gene therapy, was approved in June 2023 to treat adult patients with severe hemophilia A. Roctavian was the first one-shot gene therapy ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...